Zepbound, a drug that rivals Ozempic, may one day be a treatment for sleep apnea, according to results from a new study.

Zepbound, a popular weight loss drug, also seems to help people with obstructive sleep apnea, drugmaker Eli Lilly said ...

The results, while unpublished, are the latest in a string of hopeful signs for weight loss drugs to treat a variety of ...

A late-stage trial of Eli Lilly’s weight loss drug Zepbound showed promising results in treating sleep apnea symptoms in ...

In two trials of people with sleep apnea, Zepbound reduced the number of times breathing slowed or stopped during sleep.

Zepbound, one of the wildly popular weight-loss drugs that millions of Americans now take, eased sleep apnea in obese adults ...

The Bitcoin DeFi ecosystem displayed a stellar growth in 2024, and Mark Hendrickson believes this sector is here to stay.

Preliminary clinical trial results showed the obesity drug tirzepatide was highly effective at treating obstructive sleep ...

The company reported results of clinical trials involving Zepbound, an obesity drug in the same class as Novo Nordisk’s ...

An FDA green light could mean broader insurance coverage and a new treatment for a condition affecting 20 million Americans.

Eli Lilly noted that tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults that have both obstructive ...